Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2008

View Archived Issues

Abbott identifies novel Tie-2 inhibitors active against cancer in preclinical studies

Trial demonstrates immunomodulating effects of COLD-fX

Medtronic commences U.S. and international Endeavor Resolute stent trials

Invitrogen and Biocare to market FDA approved SPOT-Light HER2 CISH Kit

Odanacatib suppresses bone resorption in breast cancer with established bone metastases

Threshold begins phase I/II study for TH-302 in patients with soft tissue sarcoma

Temoporfin improves tumoricidal depth in photodynamic therapy for bile duct cancer

Long-term safety for Diamyd vaccination in phase II autoimmune diabetes study

GSK and XenoPort submit NDA to FDA for Solzira in restless legs syndrome

Novavax tests seasonal influenza VLP vaccine candidate in phase II trial

Neuropharma changes name to Noscira, announces completion of phase I trials of NP-12

Priority review for Coartem

Compugen discovers peptide drug candidate for treatment of solid tumors

New therapeutic agents for HCV infection disclosed in recent patents

Recent patents report novel analgesic agents

New anti-HIV agents described in recent Myriad and Novartis patents

Mymetics achieves successful results in mucosal HIV/AIDS vaccine viral challenge

Myriad presents top-line results from phase I Vivecon trial

Clinical results of PANVAC-VF in metastatic breast cancer reported

China Biologic receives SFDA approval for human coagulation factor VIII trial

Depomed initiates phase III program for Gabapentin GR in menopausal hot flashes

DXL-625 shows superiority to Rituxan in animal studies

FDA approves expanded uses for Gardasil

Oramed initiates GLP1 analogue program with ORMD-0901

Davanat data filed for registration in late-stage colorectal cancer

Merck Serono commences ORACLE MS trial to evaluate Cladribine in MS

S*BIO initiates U.S. phase I trials of oral JAK2 inhibitor SB-1518

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...